Pathogenesis of epidermolysis bullosa acquisita, an autoimmune subepidermal bullous disease

Journal of Pathology

Volumn 228, Issue 1, 2012, Pages 1-7

  Hashimoto, Takashi ^a   Ishii, Norito ^a   Ohata, Chika ^a   Furumura, Minao ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

autoantibody; autoimmune bullous disease; disease model; epidermolysis bullosa acquisita; FcgR; intravenous immunoglobulin; leukocyte; pathogenesis; therapy

Indexed keywords

ANTIGEN; AUTOANTIBODY; COLCHICINE; COLLAGEN TYPE 7; CORTICOSTEROID; DAPSONE; DESMOCOLLIN; FC RECEPTOR IIB; IMMUNOGLOBULIN; INTEGRIN; LAMININ GAMMA1; METALLOPROTEINASE; PLAKIN;

BULLOUS PEMPHIGOID; CELL MIGRATION; CLINICAL FEATURE; CYTOKINE RELEASE; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE MODEL; EPIDERMOLYSIS BULLOSA ACQUISITA; GASTROINTESTINAL DISEASE; HUMAN; HYPERLIPIDEMIA; INFECTION; LABORATORY TEST; MENTAL DISEASE; MOON FACE; NEUTROPHIL; NONHUMAN; OBESITY; OSTEOPOROSIS; PARANEOPLASTIC PEMPHIGUS; PATHOGENESIS; PEMPHIGOID; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; BLISTER; COLLAGEN TYPE VII; DISEASE MODELS, ANIMAL; EPIDERMOLYSIS BULLOSA ACQUISITA; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, KNOCKOUT; ORGAN SPECIFICITY; RECEPTORS, IGG; SKIN;

EID: 84864769042     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4062     Document Type: Review

References (81)

1. Kouno M, Kondoh G, Horie K, et al., Ahnak/Desmoyokin is dispensable for proliferation, differentiation, and maintenance of integrity in mouse epidermis. J Invest Dermatol 2004; 123: 700-707.
2. Simpson CL, Patel DM, Green KJ,. Deconstructing the skin: cytoarchitectural determinants of epidermal morphogenesis. Nat Rev Mol Cell Biol 2011; 12: 565-580.
3. Tsuruta D, Hashimoto T, Hamill KJ, et al., Hemidesmosomes and focal contact proteins: functions and crosstalk in keratinocytes, bullous diseases and wound healing. J Dermatol Sci 2011; 62: 1-7.
4. Amagai M, Stanley Jr,. Desmoglein as a target in skin disease and beyond. J Invest Dermatol 2012; 132: 776-784.
5. Hashimoto T,. Treatment strategies for pemphigus vulgaris in Japan. Expert Opin Pharmacother 2008; 9: 1519-1530.
6. Joly P, Roujeau JC, Benichou J, et al., A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346: 321-327.
7. Langan SM, Smeeth L, Hubbard R, et al., Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: population-based cohort study. Br Med J 2008; 337: a180.
8. Cines DB, Blanchette VS,. Immune thrombocytopenic purpura. N Engl J Med 2002; 346: 995-1008.
9. Yuki N,. Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes. Lancet Infect Dis 2001; 1: 29-37.
10. Durelli L, Isoardo G,. High-dose intravenous immunoglobulin treatment of multiple sclerosis. Neurol Sci 2002; 23 (suppl 1): S39-48.
11. Latov N, Chaudhry V, Koski CL, et al., Use of intravenous γ-globulins in neuroimmunologic diseases. J Allergy Clin Immunol 2001; 108: S126-132.
12. Burns JC, Glode MP,. Kawasaki syndrome. Lancet 2004; 364: 533-544.
13. Ahmed AR,. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001; 45: 679-690.
14. Jolles S,. A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders. Clin Exp Dermatol 2001; 26: 127-131.
15. Harman KE, Black MM,. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br J Dermatol 1999; 140: 865-874.
16. Shimanovich I, Nitschke M, Rose C, et al., Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 2008; 158: 382-388.
17. Ahmed AR, Spigelman Z, Cavacini LA, et al., Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355: 1772-1779.
18. Hashimoto T, Ogawa MM, Konohana A, et al., Detection of pemphigus vulgaris and pemphigus foliaceus antigens by immunoblot analysis using different antigen sources. J Invest Dermatol 1990; 94: 327-331.
19. Sugi T, Hashimoto T, Hibi T, et al., Production of human monoclonal anti-basement membrane zone (BMZ) antibodies from a patient with bullous pemphigoid (BP) by Epstein-Barr virus transformation. Analyses of the heterogeneity of anti-BMZ antibodies in BP sera using them. J Clin Invest 1989; 84: 1050-1055.
20. Tanaka H, Ishida-Yamamoto A, Hashimoto T, et al., A novel variant of acquired epidermolysis bullosa with autoantibodies against the central triple-helical domain of type VII collagen. Lab Invest 1997; 77: 623-632.
21. Kiyokawa C, Ruhrberg C, Nie Z, et al., Envoplakin and periplakin are components of the paraneoplastic pemphigus antigen complex. J Invest Dermatol 1998; 111: 1236-1238.
22. Nagata Y, Karashima T, Watt FM, et al., Paraneoplastic pemphigus sera react strongly with multiple epitopes on the various regions of envoplakin and periplakin, except for the C-terminal homologous domain of periplakin. J Invest Dermatol 2001; 116: 556-563.
23. Probst C, Schlumberger W, Stocker W, et al., Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus. Clin Chim Acta 2009; 410: 13-18.
24. Schepens I, Jaunin F, Begre N, et al., The protease inhibitor α2-macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human. PLoS One 2010; 5: e12250.
25. Arakawa M, Dainichi T, Ishii N, et al., Lesional Th17 cells and regulatory T cells in bullous pemphigoid. Exp Dermatol 2011; 20: 1022-1024.
26. Hashimoto T, Kiyokawa C, Mori O, et al., Human desmocollin 1 (Dsc1) is an autoantigen for the subcorneal pustular dermatosis type of IgA pemphigus. J Invest Dermatol 1997; 109: 127-131.
27. Hashimoto T, Amagai M, Watanabe K, et al., Characterization of paraneoplastic pemphigus autoantigens by immunoblot analysis. J Invest Dermatol 1995; 104: 829-834.
28. Mao X, Nagler AR, Farber SA, et al., Autoimmunity to desmocollin 3 in pemphigus vulgaris. Am J Pathol 2010; 177: 2724-2730.
29. Rafei D, Muller R, Ishii N, et al., IgG autoantibodies against desmocollin 3 in pemphigus sera induce loss of keratinocyte adhesion. Am J Pathol 2011; 178: 718-723.
30. Dainichi T, Kurono S, Ohyama B, et al., Anti-laminin γ1 pemphigoid. Proc Natl Acad Sci USA 2009; 106: 2800-2805.
31. Hashimoto T,. Immunopathology of IgA pemphigus. Clin Dermatol 2001; 19: 683-689.
32. Hashimoto T,. Immunopathology of paraneoplastic pemphigus. Clin Dermatol 2001; 19: 675-682.
33. Kalies K, Blessenohl M, Nietsch J, et al., T cell zones of lymphoid organs constitutively express Th1 cytokine mRNA: specific changes during the early phase of an immune response. J Immunol 2006; 176: 741-749.
34. Tashiro H, Arai H, Hashimoto T, et al., Pemphigoid nodularis: two case studies and analysis of autoantibodies before and after the development of generalized blistering. J Nihon Med Sch 2005; 72: 60-65.
35. Gammon WR, Heise ER, Burke WA, et al., Increased frequency of HLA-DR2 in patients with autoantibodies to epidermolysis bullosa acquisita antigen: evidence that the expression of autoimmunity to type VII collagen is HLA class II allele associated. J Invest Dermatol 1988; 91: 228-232.
36. Ludwig RJ, Recke A, Bieber K, et al., Generation of antibodies of distinct subclasses and specificity is linked to H2s in an active mouse model of epidermolysis bullosa acquisita. J Invest Dermatol 2011; 131: 167-176.
37. Zumelzu C, Le Roux-Villet C, Loiseau P, et al., Black patients of African descent and HLA-DRB1*15:03 frequency overrepresented in epidermolysis bullosa acquisita. J Invest Dermatol 2011; 131: 2386-2393.
38. Ludwig RJ, Muller S, Marques AD, et al., Identification of quantitative trait loci in experimental epidermolysis bullosa acquisita. J Invest Dermatol 2012; 132: 1409-1415.
39. Sitaru C, Zillikens D,. Mechanisms of blister induction by autoantibodies. Exp Dermatol 2005; 14: 861-875.
40. Kasperkiewicz M, Muller R, Manz R, et al., Heat-shock protein 90 inhibition in autoimmunity to type VII collagen: evidence that nonmalignant plasma cells are not therapeutic targets. Blood 2011; 117: 6135-6142.
41. Anhalt GJ, Labib RS, Voorhees JJ, et al., Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982; 306: 1189-1196.
42. Amagai M, Nishikawa T, Nousari HC, et al., Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J Clin Invest 1998; 102: 775-782.
43. Liu Z,. Immunopathology of bullous pemphigoid, an autoimmune and inflammatory skin blistering disease. Keio J Med 2003; 52: 128-133.
44. Fernandez AP, Kerdel FA,. The use of i.v. IG therapy in dermatology. Dermatol Ther 2007; 20: 288-305.
45. Hashimoto T, Tsuruta D, Dainichi T, et al., Demonstration of epitope spreading in bullous pemphigoid: results of a prospective multicenter study. J Invest Dermatol 2011; 131: 2175-2177.
46. Amagai M, Tsunoda K, Suzuki H, et al., Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus. J Clin Invest 2000; 105: 625-631.
47. Sitaru C,. Experimental models of epidermolysis bullosa acquisita. Exp Dermatol 2007; 16: 520-531.
48. Sitaru C, Kromminga A, Hashimoto T, et al., Autoantibodies to type VII collagen mediate Fcγ-dependent neutrophil activation and induce dermal-epidermal separation in cryosections of human skin. Am J Pathol 2002; 161: 301-311.
49. Recke A, Sitaru C, Vidarsson G, et al., Pathogenicity of IgG subclass autoantibodies to type VII collagen: induction of dermal-epidermal separation. J Autoimmun 2010; 34: 435-444.
50. Sitaru C, Mihai S, Otto C, et al., Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest 2005; 115: 870-878.
51. Woodley DT, Chang C, Saadat P, et al., Evidence that anti-type VII collagen antibodies are pathogenic and responsible for the clinical, histological, and immunological features of epidermolysis bullosa acquisita. J Invest Dermatol 2005; 124: 958-964.
52. Woodley DT, Ram R, Doostan A, et al., Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients. J Invest Dermatol 2006; 126: 1323-1330.
53. Sitaru C, Chiriac MT, Mihai S, et al., Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice. J Immunol 2006; 177: 3461-3468.
54. Ludwig RJ, Zillikens D,. Pathogenesis of epidermolysis bullosa acquisita. Dermatol Clin 2011; 29: 493-501, xi.
55. Shirahama S, Furukawa F, Yagi H, et al., Bullous systemic lupus erythematosus: detection of antibodies against noncollagenous domain of type VII collagen. J Am Acad Dermatol 1998; 38: 844-848.
56. Woodley DT, Briggaman RA, O'Keefe EJ, et al., Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med 1984; 310: 1007-1013.
57. Woodley DT, Burgeson RE, Lunstrum G, et al., Epidermolysis bullosa acquisita antigen is the globular carboxyl terminus of type VII procollagen. J Clin Invest 1988; 81: 683-687.
58. Ishii N, Yoshida M, Hisamatsu Y, et al., Epidermolysis bullosa acquisita sera react with distinct epitopes on the NC1 and NC2 domains of type VII collagen: study using immunoblotting of domain-specific recombinant proteins and postembedding immunoelectron microscopy. Br J Dermatol 2004; 150: 843-851.
59. Saleh MA, Ishii K, Kim YJ, et al., Development of NC1 and NC2 domains of type VII collagen ELISA for the diagnosis and analysis of the time course of epidermolysis bullosa acquisita patients. J Dermatol Sci 2011; 62: 169-175.
60. Komorowski L, Muller R, Vorobyev A, et al., Sensitive and specific assays for routine serological diagnosis of epidermolysis bullosa acquisita. J Am Acad Dermatol 2012; DOI:10.1016/j.jaad.2011.12.032.
61. Ishii N, Hashimoto T, Zillikens D, et al., High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases. Clin Rev Allergy Immunol 2010; 38: 186-195.
62. Csorba K, Sesarman A, Oswald E, et al., Cross-reactivity of autoantibodies from patients with epidermolysis bullosa acquisita with murine collagen VII. Cell Mol Life Sci 2010; 67: 1343-1351.
63. Ishii N, Recke A, Mihai S, et al., Autoantibody-induced intestinal inflammation and weight loss in experimental epidermolysis bullosa acquisita. J Pathol 2011; 224: 234-244.
64. Ludwig RJ, Ishii N, Kasperkiewicz M, et al., Intravenous immunoglobulin (IVIG) is effective in experimental epidermolysis bullosa acquisita. J Invest Dermatol 2008; 128: S24.
65. Hammers CM, Bieber K, Kalies K, et al., Complement-fixing anti-type VII collagen antibodies are induced in Th1-polarized lymph nodes of epidermolysis bullosa acquisita-susceptible mice. J Immunol 2011; 187: 5043-5050.
66. Shimanovich I, Mihai S, Oostingh GJ, et al., Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J Pathol 2004; 204: 519-527.
67. Chen M, Doostan A, Bandyopadhyay P, et al., The cartilage matrix protein subdomain of type VII collagen is pathogenic for epidermolysis bullosa acquisita. Am J Pathol 2007; 170: 2009-2018.
68. Watanabe N, Akikusa B, Park SY, et al., Mast cells induce autoantibody-mediated vasculitis syndrome through tumor necrosis factor production upon triggering Fcγ receptors. Blood 1999; 94: 3855-3863.
69. Yuasa T, Kubo S, Yoshino T, et al., Deletion of fcγ receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis. J Exp Med 1999; 189: 187-194.
70. Blank MC, Stefanescu RN, Masuda E, et al., Decreased transcription of the human FCGR2B gene mediated by the-343 G/C promoter polymorphism and association with systemic lupus erythematosus. Hum Genet 2005; 117: 220-227.
71. Nimmerjahn F, Ravetch JV,. Fcγ receptors as regulators of immune responses. Nat Rev Immunol 2008; 8: 34-47.
72. Baerenwaldt A, Biburger M, Nimmerjahn F,. Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol 2010; 6: 425-434.
73. Nimmerjahn F, Bruhns P, Horiuchi K, et al., FcγRIV: a novel FcR with distinct IgG subclass specificity. Immunity 2005; 23: 41-51.
74. Zhao M, Trimbeger ME, Li N, et al., Role of FcRs in animal model of autoimmune bullous pemphigoid. J Immunol 2006; 177: 3398-3405.
75. Nimmerjahn F, Lux A, Albert H, et al., FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc Natl Acad Sci USA 2010; 107: 19396-19401.
76. Nakamura A, Yuasa T, Ujike A, et al., Fcγ receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease. J Exp Med 2000; 191: 899-906.
77. Anthony RM, Wermeling F, Karlsson MC, et al., Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA 2008; 105: 19571-19578.
78. Kasperkiewicz M, Nimmerjahn F, Wende S, et al., Genetic identification and functional validation of Fcγ RIV as key molecule in autoantibody-induced tissue injury. J Pathol 2012; DOI:10.1002/path.4023.
79. Zhao W, Langfelder P, Fuller T, et al., Weighted gene coexpression network analysis: state of the art. J Biopharm Stat 2010; 20: 281-300.
80. Zhang B, Horvath S,. A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol 2005; 4:article 17.
81. Pamuk ON, Tsokos GC,. Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases. Arthritis Res Ther 2010; 12: 222.